89bio Inc (ETNB)
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s primary product candidate, pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH.
ETNB SEC Filing Email Alerts Service
ETNB SEC Filing Email Alerts Service
|
Free ETNB Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (3.60 out of 4) 63rd percentile
(ranked higher than approx. 63% of all stocks covered)
Analysts' Target Price: ETNB Stock Forecast Based on Zacks ABR data; powered by Xignite |